Provectus Biopharmaceuticals Inc.’ Abstract On Liver Cancer Accepted For Poster Presentation At European Society For Medical Oncology’s 17th World Congress On Gastrointestinal Cancer

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,, a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced today that the European Society for Medical Oncology (ESMO) has accepted the Company’s abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news